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Amiodarone inhibits the hepatic metabolism of warfarin, potentiating its anticoagulant effect.aEli Lilly Cana
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http://dx.doi.org/1However, the clinical consequences of this are not well established. Our objective in this study
was to characterize the risk of hospitalization for a hemorrhage associated with the initiation
of amiodarone within a cohort of continuous warfarin users in Ontario. We conducted
a population-based retrospective cohort study among Ontario residents aged ‡66 years
receiving warfarin. Among patients with at least 6 months of continuous warfarin therapy,
we identiﬁed those who were newly prescribed amiodarone and an equal number who were
not, matching on age, gender, year of cohort entry, and a high-dimensional propensity score.
The primary outcome was hospitalization for hemorrhage within 30 days of amiodarone
initiation. Between July 1, 1994, and March 31, 2009, we identiﬁed 60,497 patients with at
least 6 months of continuous warfarin therapy, of whom 11,665 (19%) commenced amio-
darone. For 7,124 (61%) of these, we identiﬁed a matched control subject who did not receive
amiodarone. Overall, 56 (0.8%) amiodarone recipients and 23 (0.3%) control patients were
hospitalized for hemorrhage within 30 days of initiating amiodarone (adjusted hazard ratio
2.45; 95% conﬁdence interval, 1.49e4.02). Seven of 56 (12.5%) patients hospitalized for
a hemorrhage after starting amiodarone died in hospital. In conclusion, initiation of amio-
darone among older patients receiving warfarin is associated with a more than twofold
increase in the risk of hospitalization for hemorrhage, with a relatively high fatality rate.
Physicians should closely monitor patients who initiate amiodarone while receiving
warfarin.  2013 Elsevier Inc. Open access under CC BY-NC-ND license.
(Am J Cardiol 2013;112:420e423)Amiodarone inhibits the hepaticmetabolismof (S)-warfarin
via cytochrome P450 isoenzyme 2C9, potentially accentuating
the response to warfarin.1,2 Previous studies have shown
a dose-dependent increase in the international normalized ratio
(INR) following the initiation of amiodarone therapy.1,3e13
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Open access under CC BY-NC-ND license.clinically relevant outcomes such as major hemorrhagic
events. One small study suggested no increased risk but
included a small sample size of 1,260 at-risk patients and
a short 7-day follow-up period.13 The need to better understand
this interaction and its impact on clinical outcomes is particu-
larly important as newer analogues such as dronedarone are
introduced to themarket.We sought to examine the association
between initiation of amiodarone and the short-term risk of
hemorrhage in a large sample of older patients receiving
warfarin.
Methods
We conducted a population-based retrospective cohort
study in Ontario, Canada, between July 1, 1994, and March
31, 2009, using administrative health databases. The study
was approved by the Research Ethics Board of Sunnybrook
Health Sciences Centre, Toronto, Ontario, Canada.
Prescription data were obtained from the Ontario Drug
Beneﬁt (ODB) Database, which includes claims for medica-
tions reimbursed by the provincial government for residents
aged65 years (an estimated 1.7 million people). We obtained
data from the Canadian Institute for Health Information
Discharge Abstract Database (DAD), which contains detailed
diagnostic and procedural information for all hospitalizations in
the province. We used the Ontario Health Insurance Plan
(OHIP) database to obtain information regarding physicians’
claims and the Registered Persons Database (RPDB) towww.ajconline.org
Table 1
International Statistical Classiﬁcation of Diseases and Related Health Problems, 9th revision (ICD-9), and 10th enhanced Canadian revision (ICD-10-CA)
codes used to identify hemorrhage
Outcome ICD-9 Code ICD-10 Code
Intracerebral hemorrhage 430, 431, 432.0, 432.1, 432.9 I60, I61, I62.0, I62.1, I62.9
Upper gastrointestinal hemorrhage 531.0, 531.2, 531.4, 531.6, 532.0, 532.2, 532.4, 532.6,
533.0, 533.2, 533.4, 533.6, 534.0, 534.2, 534.4, 534.6,
578.0, 578.1, 578.9
I85.0, I98.20, I98.3, K22.10, K22.12, K22.14, K22.16,
K25.0, K25.2, K25.4, K25.6, K26.0, K26.4, K26.6,
K27.0, K27.2, K27.4, K27.6, K28.0, K28.2, K28.4,
K28.6, K29.0, K31.80, K63.80
Lower gastrointestinal hemorrhage 569.3, 578.1, 578.9 K55.20, K62.5, K92.2
Other 287.8, 289, 459.0, 596.7, 599.7, 627.1, 719.1, 784.8,
786.3
N020 to N02.9, K61, N93.8, N93.9, N95.0, R04.1,
R04.2, R04.8, R04.9, R31.0, R31.1, R31.8, R58,
D68.3, H35.6, H43.1, H45.0, M25.0
Miscellaneous/Interaction Between Warfarin and Amiodarone 421determine demographic characteristics of the cohort, including
age, gender, and socioeconomic status (inferred from the
neighborhood income quintile14). All records were linked
anonymously using an encrypted health card number.
The cohort consisted of Ontario residents aged 66 years
continuously treated with warfarin for at least 6 months
during the study period, with the goal of selecting subjects
who were stable on therapy. To ensure continuous warfarin
therapy for at least 180 days, patients were required to have
at least 1 warfarin prescription in the ﬁrst 3 months and at
least 1 more in the subsequent 3 months before entering the
cohort. We did not include patients during their ﬁrst year of
eligibility for prescription drug coverage (age 65) to avoid
incomplete medication records. All subjects had access to
physician services, hospital care, and prescription drug
coverage. We excluded patients who died on the cohort
entry date as well as those with an invalid health insurance
number, missing information on age or gender, or any
previous use of amiodarone in the preceding 365 days.
Patients were followed from the cohort entry date until
hospitalization for hemorrhage, death, or 30-day maximum
follow-up, whichever occurred ﬁrst. For exposed individuals,
the cohort entry date was the date of the ﬁrst prescription for
amiodarone during the study period. For nonexposed individ-
uals, the cohort entry date was randomly assigned to generate
a similar distributionof cohort entrydates as the exposedcohort.
Each exposed patient was matched to an unexposed patient
based on age at cohort entry (within 2 years), gender, year of
cohort entry, and a high-dimensional propensity score (HDPS)
(within 0.2 SD). The HDPS algorithm empirically identiﬁes
potential confounders among measured baseline covariates
available in administrative databases.15 The process involves 7
steps: specifying data sources, empirically identifying preva-
lent covariates within these data sources, assessing recurrence
of covariates, prioritizing each covariate based on the amount
of confounding it could potentially adjust, selecting the highest
ranking covariates in addition to predeﬁned covariates, esti-
mating a propensity score using a multivariable logistic
regression model, and incorporating the propensity score into
the estimation of the exposure-outcome association. In our
study, we identiﬁed all records in the DAD, OHIP, and ODB
databases in the year before cohort entry for all patients in our
cohort and included these as dimensions in the HDPS algo-
rithm, a priori. In total, there were 5 data sets or dimensions
created (ODB claims, DAD diagnosis codes, DAD procedural
codes, OHIP fee codes, and OHIP diagnosis codes). The 200most prevalent covariates from each data set were selected and
ranked based on the amount of confounding each covariate
could reduce in the exposure-outcome association, accom-
plished by ranking the apparent relative risks of each poten-
tially confounding variable, a multiplicative function that
reﬂects the imbalance in prevalence of the variable between the
exposed and nonexposed patients and the independent asso-
ciation between this variable and the outcome of interest.15,16
We retained the 500 highest-ranking covariates. These empir-
ically derived covariates, in combination with investigator-
deﬁned covariates (i.e., age, gender, Charlson Comorbidity
Index, hospitalizations for hemorrhage in the previous year,
history of congestive heart failure, number of prothrombin
time/INR tests in the 30 days before cohort entry date, and
number of distinct drugs dispensed in past year)were entered in
a propensity score model as independent variables in the
multivariable logistic regression model.
The primary outcome was hospitalization for hemorrhage
using the Canadian modiﬁcation of the International Statis-
tical Classiﬁcation of Diseases and RelatedHealth Problems,
9th Revision and 10th Revision, Canada (Table 1). The codes
used to identify hemorrhagic events have been previously
validated, with speciﬁcity, sensitivity, and positive predictive
values exceeding 80%.17e19 We restricted our analysis to
hospitalizations in which hemorrhage was present at the time
of admission. When subjects experienced multiple outcome
events over the study period, only the ﬁrst was considered.
We used standardized differences to compare the baseline
characteristics between groups. This measure is calculated by
dividing the difference in mean values of a continuous vari-
able between the exposed and nonexposed group by the
pooled standard deviation of the variable.20 In general, values
<0.10 reﬂect clinically unimportant differences between
groups. We used Cox proportional hazards regression to
estimate the hazard ratio and 95% conﬁdence interval for the
association between initiation of amiodarone and hospitali-
zation for hemorrhage, adjusting for any baseline character-
istics that remained substantially different between groups
following matching, deﬁned as a standardized difference of
0.10. All analyses were performed using SAS version 9.2
(SAS Institute, Cary, North Carolina).
Results
We identiﬁed 60,497 patients between July 1, 1994, and
March 31, 2009 with at least 6 months of continuous
Table 2
Baseline characteristics after high-dimensional propensity score matching
Variable Warfarin Alone
(n ¼ 7,124)
Warfarin þ Amiodarone
(n ¼ 7,124)
Standardized Difference
of the Mean
Demographics
Median age at cohort entry, yrs (IQR) 76 (71e81) 76 (71e81) 0
Men 3,674 (52%) 3,674 (52%) 0
Rural location 1,054 (15%) 1,015 (14%) 0.02
Median no. hospitalizations in past yr (IQR) 1 (0e1) 0 (0e1) 0.1
Mean number of PT tests in past 30 days  SD 1.34  1.35 1.32  1.43 0.01
Charlson Comorbidity Index
0 2,136 (30%) 2,100 (30%) 0.01
1 1,304 (18%) 1,293 (18%) 0
2 1,067 (15%) 1,021 (14%) 0.02
3 674 (9%) 644 (9%) 0.01
4 862 (12%) 837 (12%) 0.01
Missing 1,081 (15%) 1,229 (17%) 0.06
Hemorrhage in past 1 yr 199 (3%) 194 (3%) 0
Heart failure in past 1 yr 1,537 (22%) 1,535 (22%) 0
Residence in long-term care facility 241 (3%) 312 (4%) 0.05
Median no. of distinct drugs prescribed in past 1 yr (IQR) 11 (8e15) 11 (8e15) 0.02
5 694 (10%) 675 (10%) 0.01
6e10 2,462 (35%) 2,586 (36%) 0.04
11e15 2,254 (32%) 2,233 (31%) 0.01
16e20 1,112 (16%) 1,042 (15%) 0.03
21e26 457 (6%) 452 (6%) 0
27 145 (2%) 136 (2%) 0.01
Medication use*
NSAIDs/non COX-2 inhibitor/non-ASA 255 (4%) 310 (4%) 0.04
COX-2 inhibitor 162 (2%) 140 (2%) 0.02
Antiplatelet agents: ASA, ticlopidine, clopidogrel,
dipyridamole, dipyridamole/ASA combination)
246 (3%) 216 (3%) 0.02
Acetaminophen and combinations 1,095 (15%) 1,037 (15%) 0.02
Gastroprotective medications (H2 receptor antagonists,
misoprostol, proton pump inhibitors, sucralfate)
1,572 (22%) 1,492 (22%) 0.03
Selective serotonin receptor inhibitors 539 (8%) 437 (6%) 0.06
Corticosteroids† 324 (5%) 339 (5%) 0.01
Statins 1,919 (27%) 1,857 (26%) 0.02
Antibiotic usez
Trimethoprim/sulfamethoxazole 21 (0.3%) 23 (0.3%) 0.01
Fluoroquinolone 83 (1%) 100 (1%) 0.02
Metronidazole 6 (0.1%) 13 (0.2%) 0.03
ASA ¼ acetylsalicylic acid (aspirin); COX-2 ¼ cyclooxygenase 2 inhibitor; H2 ¼ histamine 2 receptor antagonists; IQR ¼ interquartile range; NSAID ¼
nonsteroidal anti-inﬂammatory drugs; PT ¼ prothrombin time.
* Evidence of 1 prescription of the listed medications in the 60 days before cohort entry date.
† Excluding topical or aerosol formulations.
z Evidence of 1 prescription of the listed medications in the 14 days before cohort entry date.
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quently initiated amiodarone while receiving warfarin. Of
these, 7,124 (61%) were successfully matched to a subject
who was not exposed to amiodarone while receiving
warfarin therapy. Following matching, exposed and unex-
posed individuals were similar on baseline characteristics
(Table 2), with the exception of the median number of
hospitalizations during the year preceding cohort entry
(standardized difference ¼ 0.11). The median age was 76
years, with approximately equal percentages of men and
women (52% male).
Among the 7,124 patients who commenced amiodarone
while receiving warfarin, 50 (0.8%) were hospitalized for
hemorrhage within the subsequent 30 days. In the matched
control group, 23 (0.3%) patients were hospitalized forhemorrhage within 30 days (Table 3). We observed a signif-
icantly greater risk of hemorrhage among patients who
received amiodarone compared with patients receiving
warfarin alone (adjusted hazard ratio 2.45; 95% conﬁdence
interval, 1.49 to 4.02; Table 2). In terms of absolute risk, this
difference corresponds to a number needed to treat to harm of
216. In total, 7 (12.5%) patients hospitalized for hemorrhage
following the initiation of amiodarone, died in hospital.
Discussion
In this population-based cohort study spanning 15 years,
we found that patients receiving warfarin were also frequently
prescribed amiodarone. This is not surprising given the utility
of both drugs for atrial ﬁbrillation. However, the prevalence
Table 3
Primary outcome: patients admitted hemorrhagic event (primary event)
Warfarin Alone Warfarin þ Amiodarone
No. of individuals N ¼ 7,124 N ¼ 7,124
Total follow-up (person yrs) 581 577
Follow-up (days  SD) 30  2 30  3
Number of patients with
a hemorrhage
23 56
Incidence 0.3% 0.8%
No. needed to harm Reference 216
Unadjusted HR (95% CI) 1.0 2.43 (1.50e3.96)
Adjusted HR (95% CI) 1.0 2.45 (1.49e4.02)
HRs were adjusted for hospitalizations prior to cohort entry.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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the potential for an adverse drug interaction between warfarin
and amiodarone. Our results suggest that patients receiving
chronic warfarin therapy face a more than twofold-increased
risk of hospitalization for hemorrhage within 30 days of
starting amiodarone. Overall, roughly 1% of patients started
on amiodarone during warfarin therapy were hospitalized for
hemorrhage in the subsequent 30 days.
Our ﬁndings have strong biologic plausibility but differ
from those of previous research by Zhang et al.13 Our cohort
was >10 times larger, we followed patients for a longer
period of time, and we compared amiodarone users with
a well-matched reference group. Furthermore, our results are
consistent with evidence showing that that this interaction
exaggerates the hypoprothrombinemic response to
warfarin.1e13 Although hemorrhage can occur at therapeutic
INR levels, INRs above the therapeutic range are associated
with a higher risk of major hemorrhage.21
Some limitations of our study merit emphasis. First, we
could not assess unmeasured variables such as use of
nonprescription medications or diets that interact with
warfarin. Although exposed and unexposed patients were
closely matched on measured characteristics, it is impossible
in an observational study to achieve the level of balance for
unmeasured characteristics attainable in a randomized
controlled trial.22 Second, although we were able to deter-
mine the frequency of INR testing using OHIP billing codes,
we could not directly obtain the values and so were unable to
measure INR control to identify patients at risk of bleeding or
determine a correlation between hospitalization for bleeding
and supratherapeutic INR values. Our results derive from
patients aged 66 years, and the generalizability to younger
patients is unknown. Also, we could not account for less
severe bleeds that did not lead to hospital admission or very
severe bleeds that led to death in the prehospital setting.
Finally, our study was not designed to describe or control for
the indication of warfarin or amiodarone therapy.
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